Epigral Ltd (IN:EPIGRAL)
:EPIGRAL
Top Page
Epigral Ltd
(EPIGRAL)
Select Model
Select Model
Rating:67Neutral
Price Target:
₹977.00
▼(-21.48% Downside)
Action:ReiteratedDate:02/04/26
Overall score is supported primarily by strong financial performance (improving growth, solid profitability, and materially better free cash flow), but is held back by weak technicals with the stock trading below key moving averages and negative MACD. Valuation is reasonable on P/E, though the dividend yield is low.
Positive Factors
Free Cash Flow Recovery
Epigral’s turn to positive free cash flow in 2025, together with a strong operating cash flow to net income ratio, indicates durable cash generation. This supports capital spending, debt paydown and reinvestment capacity, improving financial flexibility through cycles.
Negative Factors
Substantial Absolute Debt
Although leverage ratios have improved, the company’s absolute debt level remains substantial. High debt can elevate interest costs, constrain strategic investments and limit weathering prolonged downturns if cash flows weaken or capex needs rise over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Free Cash Flow Recovery
Epigral’s turn to positive free cash flow in 2025, together with a strong operating cash flow to net income ratio, indicates durable cash generation. This supports capital spending, debt paydown and reinvestment capacity, improving financial flexibility through cycles.
Read all positive factors
Epigral Ltd (EPIGRAL) vs. iShares MSCI India ETF (INDA)
Market Cap
₹47.48B
Dividend Yield0.46%
Average Volume (3M)1.86K
Price to Earnings (P/E)33.6
Beta (1Y)1.47
Revenue Growth8.51%
EPS Growth32.37%
CountryIN
Employees997
SectorHealthcare
Sector Strength45
IndustryChemicals
Share Statistics
EPS (TTM)9.10
Shares Outstanding43,141,340
10 Day Avg. Volume1,295
30 Day Avg. Volume1,859
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)4.21
Price to Sales (P/S)3.14
P/FCF Ratio32.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)65.75
Revenue Forecast (FY)₹28.31B
Epigral Ltd Business Overview & Revenue Model
Company Description
Epigral Limited manufactures and sells chlor-alkali and related derivatives in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes, hydrogen peroxide, caustic soda, chlorine, ...
How the Company Makes Money
Epigral primarily makes money by manufacturing and selling bulk and value-added chemicals. Its key revenue stream is the sale of chlor-alkali products—most notably caustic soda (a high-volume industrial alkali)—to a broad base of industrial custom...
Epigral Ltd Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.67B | 25.50B | 18.94B | 21.69B | 15.50B | 8.26B |
| Gross Profit | 11.21B | 10.67B | 7.79B | 6.43B | 7.48B | 4.13B |
| EBITDA | 6.61B | 7.11B | 4.77B | 6.81B | 5.01B | 2.66B |
| Net Income | 4.02B | 3.58B | 1.96B | 3.53B | 2.53B | 1.01B |
Balance Sheet | ||||||
| Total Assets | 32.36B | 31.52B | 27.94B | 24.32B | 21.24B | 14.49B |
| Cash, Cash Equivalents and Short-Term Investments | 485.70M | 965.00M | 31.83M | 142.40M | 250.85M | 6.80M |
| Total Debt | 5.37B | 5.93B | 9.64B | 8.79B | 9.93B | 5.42B |
| Total Liabilities | 11.35B | 12.48B | 15.40B | 13.63B | 13.98B | 7.65B |
| Stockholders Equity | 21.01B | 19.05B | 12.54B | 10.69B | 7.26B | 6.84B |
Cash Flow | ||||||
| Free Cash Flow | 316.30M | 2.46B | -7.90M | 2.10B | -1.72B | 324.17M |
| Operating Cash Flow | 2.67B | 4.41B | 3.98B | 6.26B | 2.84B | 2.29B |
| Investing Cash Flow | -1.73B | -2.62B | -4.01B | -4.37B | -4.55B | -1.97B |
| Financing Cash Flow | -980.80M | -1.64B | -75.98M | -2.00B | 1.95B | -319.00M |
Epigral Ltd Technical Analysis
Neutral
1244.30
Price Trends
936.21
Positive
1140.09
Negative
1457.25
Negative
Market Momentum
6.95
Negative
66.60
Neutral
93.32
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:EPIGRAL, the sentiment is Neutral. The current price of 1244.3 is above the 20-day moving average (MA) of 882.22, above the 50-day MA of 936.21, and below the 200-day MA of 1457.25, indicating a neutral trend. The MACD of 6.95 indicates Negative momentum. The RSI at 66.60 is Neutral, neither overbought nor oversold. The STOCH value of 93.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:EPIGRAL.
Epigral Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹80.96B | 18.03 | ― | 0.44% | 14.80% | 1.35% | |
68 Neutral | ₹51.34B | 30.45 | ― | 0.13% | 14.35% | 15.79% | |
67 Neutral | ₹47.48B | 33.65 | ― | 0.46% | 8.51% | 32.37% | |
65 Neutral | ₹92.23B | 10.27 | ― | 0.41% | 6.22% | 123.83% | |
57 Neutral | ₹30.21B | 67.80 | ― | 0.03% | 7.78% | -34.68% | |
54 Neutral | ₹82.12B | 35.22 | ― | 0.16% | 10.46% | 111.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:EPIGRAL
Epigral Ltd
1,100.65
-731.90
-39.94%
IN:GUFICBIO
Gufic Biosciences Limited
301.20
-40.21
-11.78%
IN:MARKSANS
Marksans Pharma Limited
178.65
-31.66
-15.05%
IN:SHILPAMED
Shilpa Medicare Limited
419.90
92.85
28.39%
IN:STAR
Strides Pharma Science Ltd
1,000.65
384.38
62.37%
IN:SUPRIYA
Supriya Lifescience Limited
637.95
-93.89
-12.83%
Epigral Ltd Corporate Events
Epigral Board Clears Q3 and Nine-Month FY25 Unaudited Results
Jan 30, 2026
Epigral Limited reported that its board of directors met on January 30, 2026, at the company’s registered office in Ahmedabad. At this meeting, the board approved the company’s unaudited standalone and consolidated financial results fo...
Epigral’s Q3 Profit Slides on Margin Pressure as Capex-Led Growth Plans Stay on Track
Jan 30, 2026
Epigral Limited reported Q3 FY26 revenue of ₹603 crore, down from ₹649 crore a year earlier, with profit after tax falling to ₹39 crore from ₹104 crore as margins were hit by softer realizations, higher raw material costs a...
Epigral Releases Investor Presentation on Q3 FY26 Unaudited Results
Jan 30, 2026
Epigral Limited has notified the stock exchanges that it has released an investor presentation detailing its unaudited financial results for the third quarter of fiscal year 2026. The earnings presentation, which has been filed in compliance with ...
Epigral Plans One-on-One VC Meet With UTI AMC on 16 January
Jan 15, 2026
Epigral Ltd has notified stock exchanges that it will hold a one-on-one video conference meeting with UTI Asset Management Company Ltd, an investor and analyst, on 16 January 2026. The company stated that it will use its existing earnings and corp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.